Serum Ceruloplasmin Level as a Predictor for the Progression of Diabetic Nephropathy in Korean Men with Type 2 Diabetes Mellitus

다국어 초록 (Multilingual Abstract)

Background: Oxidative stress is known to be associated with progression of diabetic kidney disease. Ceruloplasmin acts as a pro-oxidant under conditions of severe oxidative stress. Thus, we conducted a longitudinal observational study to evaluate whether the serum ceruloplasmin level is a predictive biomarker for progression of diabetic nephropathy.
Methods: A total of 643 Korean men with type 2 diabetes mellitus were enrolled. Serum ceruloplasmin was measured using a nephelometric method. Progression of diabetic nephropathy was defined as transition in albuminuria class (i.e., normoalbuminuria to microalbuminuria, microalbuminuria to macroalbuminuria, or normoalbuminuria to macroalbuminuria) and/or a greater than 2-fold increase of serum creatinine at follow-up compared with the baseline value.
Results: During the follow-up period (median, 2.7 years; range, 0.3 to 4.4 years), 49 of 643 patients (7.6%) showed the progression of diabetic nephropathy and three patients (0.5%) developed end-stage renal disease. Baseline ceruloplasmin levels were higher in the progressors than in the nonprogressors (262.6±40.9 mg/L vs. 233.3±37.8 mg/L, P<0.001). Kaplan-Meier analysis showed a significantly higher incidence of nephropathy progression according to ceruloplasmin tertile (log-rank test, P<0.001).
The hazard ratio (HR) for progression of diabetic nephropathy was significantly higher in the highest ceruloplasmin tertile category compared with the lowest ceruloplasmin tertile category, even after adjusting for confounding variables (HR, 3.32; 95% confidence interval, 1.28 to 8.61; P=0.003).
Conclusion: Baseline serum ceruloplasmin is an independent predictive factor for the progression of diabetic nephropathy in patients with type 2 diabetes mellitus.

참고문헌 (Reference)

1 Hellemons ME, "Validity of biomarkers predicting onset or progression of nephropathy in patients with type 2 diabetes: a systematic review" 29 : 567-577, 2012

2 Zhang Y, "Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic beta cells" 375 : 89-96, 2013

3 Jalal DI, "Uric acid as a mediator of diabetic nephropathy" 31 : 459-465, 2011

4 Brenner BM, "The hyperfiltration theory: a paradigm shift in nephrology" 49 : 1774-1777, 1996

5 Gordois A, "The health care costs of diabetic nephropathy in the United States and the United Kingdom" 18 : 18-26, 2004

6 de Boer IH, "Temporal trends in the prevalence of diabetic kidney disease in the United States" 305 : 2532-2539, 2011

7 Retnakaran R, "Risk factors for renal dysfunction in type 2diabetes: U.K. Prospective Diabetes Study 74" 55 : 1832-1839, 2006

8 Hsu CY, "Risk factors for end-stage renal disease: 25-year follow-up" 169 : 342-350, 2009

9 Kramer HJ, "Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus" 289 : 3273-3277, 2003

10 de Zeeuw D, "Proteinuria, a target for renoprotection in patients with type 2diabetic nephropathy: lessons from RENAAL" 65 : 2309-2320, 2004

11 Kedziora-Kornatowska K, "Production of nitric oxide, lipid peroxidation and oxidase activity of ceruloplasmin in blood of elderly patients with primary hypertension. Effects of perindopril treatment" 18 : 1-6, 2006

12 Narita T, "Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients" 27 : 1176-1181, 2004

13 Molitch ME, "Nephropathy in diabetes" 27 (27): S79-S83, 2004

14 Memisogullari R, "Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with type 2diabetes mellitus" 18 : 193-197, 2004

15 Afkarian M, "Kidney disease and increased mortality risk in type 2 diabetes" 24 : 302-308, 2013

16 UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" 352 : 837-853, 1998

17 Navarro JF, "Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus" 42 : 53-61, 2003

18 Wada J, "Inflammation and the pathogenesis of diabetic nephropathy" 124 : 139-152, 2013

19 Daimon M, "Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 diabetes" 21 : 1525-1528, 1998

20 Jung CH, "Elevated serum ceruloplasmin levels are associated with albuminuria in Korean men with type 2 diabetes mellitus" 94 : e3-e7, 2011

21 Cunningham J, "Elevated plasma ceruloplasmin in insulin-dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication" 44 : 996-999, 1995

22 Bakris GL, "Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study" 163 : 1555-1565, 2003

23 Shukla N, "Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor?" 187 : 238-250, 2006

24 Williams ME, "Diabetic nephropathy: the proteinuria hypothesis" 25 : 77-94, 2005

25 Sontakke AN, "Changes in serum ceruloplasmin levels with commonly used methods of contraception" 19 : 102-104, 2004

26 Ujihara N, "Association between plasma oxidized low-density lipoprotein and diabetic nephropathy" 58 : 109-114, 2002

27 Milne DB, "Assessment of copper status: effect of age and gender on reference ranges in healthy adults" 39 : 883-887, 1993

28 Harris ZL, "Aceruloplasminemia" 207 : 108-109, 2003

29 Levey AS, "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group" 130 : 461-470, 1999